Every 10-Q that BIOATLA INC (BCAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.
BioAtla, Inc. is a clinical-stage oncology company focused on conditionally active biologics. For the quarter ended June 30, 2026, it reported $6.5 million of collaboration revenue, entirely from amending its license with Context Therapeutics, and net income of $0.5 million, versus a $18.7 million loss a year earlier. Operating expenses fell sharply as Phase 2 trials concluded and a major restructuring was implemented.
Despite the profitable quarter, BioAtla recorded a $5.9 million loss for the first half of 2026, an accumulated deficit of $551.5 million, and cash and cash equivalents of just $1.5 million. Management disclosed substantial doubt about its ability to continue as a going concern. The company is pursuing strategic alternatives, has reduced its workforce by about 70%, paused new enrollment in its BA3182 Phase 1 trial, and is reassessing timelines for a potential Phase 3 study of BA3021. Liquidity actions include converting a $7.5 million pre-paid advance into equity and limited use of a $15 million standby equity purchase agreement.
BioAtla, Inc. reported a Q1 2026 net loss of $6.3M, improved from $15.3M a year earlier, mainly due to sharply lower research and development spending after completing several Phase 2 trials and cutting its workforce.
Research and development expense fell to $4.6M from $12.4M, while general and administrative costs were stable at $4.7M. The company recorded a $2.7M non-cash gain from revaluing warrant liabilities and a $0.3M gain from remeasuring a pre-paid advance that fully converted into equity.
Liquidity remains constrained: cash and cash equivalents were only $2.0M at March 31, 2026, against an accumulated deficit of $552.0M, and management concluded that substantial doubt exists about its ability to continue as a going concern. In March 2026 BioAtla launched a strategic review and implemented a ~70% workforce reduction to preserve capital. A May 2026 amendment to a license agreement with Context Therapeutics is expected to bring $6.5M in non-recurring cash, and the company also has access to a $15.0M standby equity facility, but future funding and the outcome of the strategic process remain uncertain.
BioAtla (BCAB) reported Q3 2025 results, highlighting a continued operating loss and liquidity pressure. The company recorded a quarterly net loss of $15.8 million (net loss per share $0.27) and a year‑to‑date net loss of $49.8 million. There was no collaboration revenue in the quarter, versus $11.0 million a year ago.
Operating expenses fell as programs wound down: R&D was $9.5 million (down from $16.4 million) and G&A was $4.3 million (down from $5.9 million). Cash and cash equivalents were $8.3 million at September 30, 2025, down from $49.0 million at year‑end, and management concluded there is “substantial doubt” about the ability to continue as a going concern.
The balance sheet showed total liabilities of $47.1 million, including a $19.8 million licensor liability and a $4.3 million warrant liability, resulting in stockholders’ deficit of $(31.2) million. Shares outstanding were 58,792,088 as of November 10, 2025. A subsequent event notes receipt of a $2.0 million milestone under the Context license.